<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04142749</url>
  </required_header>
  <id_info>
    <org_study_id>PMK-N01GI1-P3</org_study_id>
    <nct_id>NCT04142749</nct_id>
  </id_info>
  <brief_title>Oltipraz for Liver Fat Reduction in Patients With Non-alcoholic Fatty Liver Disease Except for Liver Cirrhosis</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Oltipraz</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaKing</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmaKing</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oltipraz inhibits fatty acid synthesis through AMPK-S6K1 pathway and LXRg-SREBP-1c pathway in&#xD;
      liver.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dithiolethiones, a novel class of adenosine monophosphate-activated protein kinase (AMPK)&#xD;
      activators, prevent insulin resistance through AMPK-dependent p70 ribosomal S6 kinase-1&#xD;
      (S6K1) inhibition. And it is well known that the modulation of S6K1 by oltipraz inhibited the&#xD;
      development of insulin resistance and hyperglycemia through the AMPK-S6K1 pathway.Also some&#xD;
      research reported that LXRg (a member of the nuclear hormone receptor)-mediated increases in&#xD;
      SREBP-1c (the sterol regulatory element-binding protein-1c gene) promote the expression of&#xD;
      lipogenic genes and enhance fatty acid synthesis and oltipraz inhibits LXRg and SREBP-c.&#xD;
      Therefore, Oltipraz inhibits fatty acid synthesis through AMPK-S6K1 pathway and LXRg-SREBP-1c&#xD;
      pathway in liver.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variation of liver fat assessed</measure>
    <time_frame>24 weeks compared to the baseline</time_frame>
    <description>Variation of liver fat assessed by MRS at 24 weeks compared to the baseline (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The variation in the amount of liver fat</measure>
    <time_frame>24 weeks compared to the baseline</time_frame>
    <description>The variation in the amount of liver fat assessed by the MRS at the time of 24 weeks compared to the baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of liver fat certificate grade</measure>
    <time_frame>24 weeks compared to the baseline</time_frame>
    <description>Variation of liver fat certificate grade assessed by ultrasonic waves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of NFS variation</measure>
    <time_frame>24 weeks compared to the baseline</time_frame>
    <description>Variation of NFS at 24 weeks compared to the baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of liver elasticities and fatty acids</measure>
    <time_frame>24 weeks compared to the baseline</time_frame>
    <description>Variation of liver elasticities and fatty acids assessed by fibroscan at 24 weeks time compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FIB-4</measure>
    <time_frame>8 weeks, 16 weeks and 24 weeks</time_frame>
    <description>Variation of FIB-4 from 8 weeks, 16 weeks and 24 weeks to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>8 weeks, 16 weeks and 24 weeks</time_frame>
    <description>BMI variation at 8 weeks, 16 weeks and 24 weeks relative to the baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of ALT, AST, γ-glutamyl transferase (GGT)</measure>
    <time_frame>8 weeks, 16 weeks and 24 weeks</time_frame>
    <description>Variation of ALT, AST, γ-glutamyl transferase (GGT) in time of 8 weeks, 16 weeks and 24 weeks relative to the baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol (total, low-density lipoprotein (LDL), high-density lipoprotein (HDL), very low-density lipoprotein (VLDL), triglyceride (TG)</measure>
    <time_frame>8 weeks, 16 weeks and 24 weeks</time_frame>
    <description>Variation of Cholesterol (total, low-density lipoprotein (LDL), high-density lipoprotein (HDL), very low-density lipoprotein (VLDL), triglyceride (TG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of Homeostatic model adjustment-insulin resistance (HOMA-IR) index</measure>
    <time_frame>24 weeks compared to the baseline</time_frame>
    <description>Variation of Homeostatic model adjustment-insulin resistance (HOMA-IR = fasting insulin (μU/mL) × fasting glucose (mmol/L) / 22.5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>24 weeks compared to the baseline</time_frame>
    <description>The variation of waist circumference compared to the baseline at 24 weeks</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The Variation of biomarkers</measure>
    <time_frame>8 weeks, 16 weeks and 24 weeks</time_frame>
    <description>Adipokine (leptin, adiponectin, resistin, TNF-α, IL-6)</description>
  </other_outcome>
  <other_outcome>
    <measure>The Variation of biomarkers</measure>
    <time_frame>8 weeks, 16 weeks and 24 weeks</time_frame>
    <description>CK-18 (M30, M65)</description>
  </other_outcome>
  <other_outcome>
    <measure>The Variation of biomarkers</measure>
    <time_frame>8 weeks, 16 weeks and 24 weeks</time_frame>
    <description>Hepcidine</description>
  </other_outcome>
  <other_outcome>
    <measure>Variation of liver fat assessed as tissue samples acquired by liver biopsy</measure>
    <time_frame>24 weeks compared to the baseline</time_frame>
    <description>Variation of liver fat assessed as tissue samples acquired by liver biopsy at 24 weeks compared to the baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Variation of Steatosis assessed as tissue samples acquired by liver biopsy</measure>
    <time_frame>24 weeks compared to the baseline</time_frame>
    <description>Variation of Steatosis at 24 weeks compared to the baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Variation of lobular inflammation assessed as tissue samples acquired by liver biopsy</measure>
    <time_frame>24 weeks compared to the baseline</time_frame>
    <description>Variation of lobular inflammation at 24 weeks compared to the baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Variation of ballooning assessed as tissue samples acquired by liver biopsy</measure>
    <time_frame>24 weeks compared to the baseline</time_frame>
    <description>Variation of ballooning at 24 weeks compared to the baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>NAFLD activity scores (NAS)</measure>
    <time_frame>24 weeks compared to the baseline</time_frame>
    <description>Variation of NAFLD activity scores (NAS) at 24 weeks compared to the baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation between MRS and ultrasound, fibroscan, FIB-4, and biopsy results</measure>
    <time_frame>24 weeks compared to the baseline</time_frame>
    <description>Correlation between MRS and ultrasound, fibroscan, FIB-4, and biopsy results</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Oltipraz</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oltipraz 30mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 30mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oltipraz</intervention_name>
    <description>Total 90mg, By mouth, TID</description>
    <arm_group_label>Oltipraz</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Total 90mg, By mouth, TID</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A person the ages of 19 and 75 years old&#xD;
&#xD;
          -  Patients with non-alcoholic fatty liver disease other than cirrhosis that meets all of&#xD;
             the following criteria:&#xD;
&#xD;
               1. Abdominal ultrasonography of Screening indicates that the liver is brighter than&#xD;
                  the spleen or kidneys, causing suspected fatty liver&#xD;
&#xD;
               2. Persons with liver fat content is 20% or more on the MRS&#xD;
&#xD;
               3. Those who do not have significant alcohol intake within two years before&#xD;
                  screening (men: no more than 210 g per week; women: no more than 140 g per week)&#xD;
&#xD;
               4. Those who with an alcohol use disorder identification test (AUDIT) result point&#xD;
                  is no more than 7, during screening.&#xD;
&#xD;
          -  Persons with body mass index (BMI) more than 23 kg/m2 during screening&#xD;
&#xD;
          -  A person who satisfies the following laboratory test results when screening&#xD;
&#xD;
               1. Platelet ≥ 130,000/㎣&#xD;
&#xD;
               2. White blood cell (WBC) ≥ 3,000/㎣&#xD;
&#xD;
               3. Absolute neutrophil count (ANC) ≥ 1,500/㎣&#xD;
&#xD;
               4. Albumin ≥ 3.5 g/dL&#xD;
&#xD;
               5. Serum creatinine ≤ 1.5 X upper limit of normal (ULN)&#xD;
&#xD;
               6. ULN &lt; Alanine transaminase (ALT) or aspartate transaminase (AST) ≤ 250 IU/L&#xD;
&#xD;
          -  A person who is willing to maintain the same lifestyle (exercise, alcohol intake,&#xD;
             diet, etc.) maintained for at least four weeks before screening during the clinical&#xD;
             trial period.&#xD;
&#xD;
          -  A person who voluntarily agrees to participate in this clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A person who has history of following disease or surgery&#xD;
&#xD;
               1. Malignant tumour with liver cancer&#xD;
&#xD;
               2. Malignant tumor excluding liver cancer, However, registration is possible in the&#xD;
                  following cases&#xD;
&#xD;
                    1. If the investigator determines that the patient has been completely cured&#xD;
                       after maintaining the condition for at least five years&#xD;
&#xD;
                    2. In case of basal cell or squamous cell carcinoma of the skin, the patient is&#xD;
                       able to maintain a complete condition for more than three years in the case&#xD;
                       of cainoma in the cervix (CIN) and carcinema in situ (CIS), and other areas.&#xD;
&#xD;
               3. autoimmune disease (e.g., inflammatory bowel disease, autoimmune hemolytic&#xD;
                  disease, idiopathic thrombocytopenic purpura, systemic lupus erythematosus,&#xD;
                  rheumatoid arthritis, severe psoriasis, etc.)&#xD;
&#xD;
               4. Bariatric surgery within 24 weeks before screening&#xD;
&#xD;
          -  A Person who has comorbidity of the following diseases at the time of screening&#xD;
&#xD;
               1. Liver cirrhosis identified by an epidemiological or histological examination&#xD;
&#xD;
               2. Cumulative disease (e.g., alcohol liver disease, toxic hepatitis, autoimmune&#xD;
                  liver disease, metabolic liver disease, biliary closure, etc.) that may indicates&#xD;
                  liver abnormalities other than non-alcoholic fatty liver disease&#xD;
&#xD;
               3. A Person who has been infected or has Hepatitis B Virus (HBV) or Hepatitis C&#xD;
                  Virus (HCV).&#xD;
&#xD;
               4. Type 1 diabetes or type 2 diabetes (hemoglobin A1c (HbA1c) &gt; 9%)&#xD;
&#xD;
               5. A person who has positive result of Human immunodeficiency virus antibody (HIV&#xD;
                  Ab).&#xD;
&#xD;
               6. A persons with conditions that may affect the effectiveness and safety by&#xD;
                  investigator&#xD;
&#xD;
          -  A person with AST/ALT ratio of more than 2 at screening&#xD;
&#xD;
          -  The person who has the following medication history&#xD;
&#xD;
               1. Persons administered vitamin E (≥ 800 IU/day) or thiazolidatedione drugs or&#xD;
                  glucagon-like peptide-1 (GLP-1) agonist drugs within 12 weeks prior to screening&#xD;
&#xD;
               2. Persons who were given antiobestic drug within 12 weeks of screening For example;&#xD;
                  antiobestic drug with Central nervous system action: Amfepramone, bupropion and&#xD;
                  naltrexone, cathine, clobenzorex, dexfenfluramine, ephedrine combinations,&#xD;
                  etilamfetamine, fenfluramine, lorcaserin, mazindol, mefenorex, phentermine,&#xD;
                  sibutramine, Peripheral neurotic Obesity drugs: Orlistat, Rimonabant, etc&#xD;
&#xD;
               3. A person who received medications that could cause fatty liver disease within 8&#xD;
                  weeks prior to screening For example; Administration of systemic glucocorticoids&#xD;
                  for more than two weeks Anabolic steroid-based drug, Estrogen-based drug,&#xD;
                  Azole-based antimicrobial agent, Nucleoside, Nucleotide reverse transcriptase&#xD;
                  inhibitor-based drug, Tetracycline-based drug, Amiodarone, tamoxifen,&#xD;
                  methotrexate, valproic acid, etc&#xD;
&#xD;
               4. A person who administered drugs that may affect the progress of non-alcoholic&#xD;
                  fatty liver disease within 4 weeks prior to screening or who require&#xD;
                  administration during clinical trials For example; Silymarin, biphenyl dimethyl&#xD;
                  dicarboxylate (DDB), ursodeoxycholic acid (UDCA), S-adenosyl-L-methionine (SAMe),&#xD;
                  betaine, pentoxyfylline, sodium-glucose cotransporter-2 (SGLT-2) inhibitor, omega&#xD;
                  3 fatty acid, etc.&#xD;
&#xD;
                    1. However, the following drugs can be registered if they are under stable&#xD;
                       dosage for at least 12 weeks and are expected to remain unchanged during&#xD;
                       clinical trials; Sulfonylurea-based drug, metformin, insulin, dipeptidyl&#xD;
                       peptidase-4 inhibitor (DPP-4 inhibitor), a-glucosidase inhibitor (a-GI),&#xD;
                       meglitinide-based drug, statin-based drug, fibrate-based drug, nicotinic&#xD;
                       acid, ezetimibe, beta-blockers based drug, thiazide based drug&#xD;
&#xD;
          -  A person who receive non-drug treatment that may affect the liver within 4 weeks prior&#xD;
             to screening.&#xD;
&#xD;
          -  A person who administered/treated with other clinical trials/medical devices within 4&#xD;
             weeks prior to screening&#xD;
&#xD;
          -  Those who are not able to MRS(I)&#xD;
&#xD;
          -  A female who is pregnant, may be pregnant, or is lactating&#xD;
&#xD;
          -  A person who is not willing to use appropriate contraceptives during this clinical&#xD;
             trial.&#xD;
&#xD;
          -  A person who is hypersensitive to the Investigational Product&#xD;
&#xD;
          -  A person who is deemed ineligible for clinical trials by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yun-Jun Kim, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul Nat'l Uni. Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Changuk Kim, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea, Uijeongbu ST. Mary's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gapjin Chun, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gangneung Asan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Taehui Lee, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kunyang University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Byeongguk Jang, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Keimyung University Dongsan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seonguk Lee, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dong-A University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Byeonggwan Kim, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boramae Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yeongseok Kim, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soonchunhyang University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jaeyeong Chang, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soonchunhyang University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jaeyeong Jung, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ajou University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hyeonung Lee, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University Gangnam Severance Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Doyeong Kim, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Munyeong Kim, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wonju Severance Christian Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Junseong Lee, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University Ilsan Baek Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jinu Lee, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inha University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hyeongjun Kim, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chung-Ang University Hosptial, Chung-Ang University College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sanghun Park, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hallym University Gangnam Sungsim Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daewon Jun, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanyang University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chun Kyun Lee, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Health Insurance Service Ilsan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min-Goo Yang, Director</last_name>
    <phone>+82269254063</phone>
    <email>mg8023@hanmail.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jenny kim, PM</last_name>
    <phone>+82269254063</phone>
    <email>loveje00@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Inje University Ilsan Paik Hospital</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>411-706</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junseong Lee, MD.PhD</last_name>
    </contact>
    <investigator>
      <last_name>Junseong Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Uijeongbu ST. Mary's Hospital</name>
      <address>
        <city>Uijeongbu-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changuk Kim, MD.PhD</last_name>
    </contact>
    <investigator>
      <last_name>Changuk Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <state>Junggu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinu Lee, MD.PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jinu Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University Bucheon Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yeongseok Kim, MD.PhD</last_name>
    </contact>
    <investigator>
      <last_name>Yeongseok Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PI</last_name>
      <phone>+8251-240-2000</phone>
    </contact>
    <investigator>
      <last_name>Seonguk Lee, MD.PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byeongguk Jang, MD.PhD</last_name>
    </contact>
    <investigator>
      <last_name>Byeongguk Jang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kunyang University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Gangneung Asan Medical Center</name>
      <address>
        <city>Gangneung-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gapjin Chun, MD.PhD</last_name>
    </contact>
    <investigator>
      <last_name>Gapjin Chun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHUS Ilsan Hospital</name>
      <address>
        <city>Goyang-si</city>
        <zip>410-719</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chun Kyun Lee, MD.PhD</last_name>
      <phone>82-31-900-0028</phone>
    </contact>
    <investigator>
      <last_name>Cheon Gyun Lee, M.D.Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>82-2-2072-2386</phone>
    </contact>
    <investigator>
      <last_name>Yoonjun Kim, MD.PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boramae Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>82-2-870-2861</phone>
    </contact>
    <investigator>
      <last_name>Byeong-Gwan Kim, MD.PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hosptial</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyeongjun Kim, MD.PhD</last_name>
    </contact>
    <investigator>
      <last_name>Hyeongjun Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hallym University Gangnam Sungsim Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanghun Park, MD.PhD</last_name>
    </contact>
    <investigator>
      <last_name>Sanghun Park</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hanyang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daewon Jun, MD.PhD</last_name>
    </contact>
    <investigator>
      <last_name>Daewon Jun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doyeong Kim, MD.PhD</last_name>
    </contact>
    <investigator>
      <last_name>Doyeong Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University Seoul Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaeyeong Chang, MD.PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jaeyeong Chang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yonsei University Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyeonung Lee, MD.PhD</last_name>
    </contact>
    <investigator>
      <last_name>Hyeonung Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ajou University School of Medicine</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaeyeong Jung, MD.PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jaeyeong Jung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wonju Severance Christian Hospital</name>
      <address>
        <city>Wanju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Munyeong Kim, MD.PhD</last_name>
    </contact>
    <investigator>
      <last_name>Munyeong Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>September 19, 2019</study_first_submitted>
  <study_first_submitted_qc>October 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oltipraz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

